Literature DB >> 22493541

Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal.

Lucy Vannella, Edith Lahner, Bruno Annibale.   

Abstract

Chronic atrophic gastritis (CAG) is an inflammatory condition characterized by the loss of gastric glandular structures which are replaced by connective tissue (non-metaplastic atrophy) or by glandular structures inappropriate for location (metaplastic atrophy). Epidemiological data suggest that CAG is associated with two different types of tumors: Intestinal-type gastric cancer (GC) and type I gastric carcinoid (TIGC). The pathophysiological mechanisms which lead to the development of these gastric tumors are different. It is accepted that a multistep process initiating from Helicobacter pylori-related chronic inflammation of the gastric mucosa progresses to CAG, intestinal metaplasia, dysplasia and, finally, leads to the development of GC. The TIGC is a gastrin-dependent tumor and the chronic elevation of gastrin, which is associated with CAG, stimulates the growth of enterochromaffin-like cells with their hyperplasia leading to the development of TIGC. Thus, several events occur in the gastric mucosa before the development of intestinal-type GC and/or TIGC and these take several years. Knowledge of CAG incidence from superficial gastritis, its prevalence in different clinical settings and possible risk factors associated with the progression of this condition to gastric neoplasias are important issues. This editorial intends to provide a brief review of the main studies regarding incidence and prevalence of CAG and risk factors for the development of gastric neoplasias.

Entities:  

Keywords:  Chronic atrophic gastritis; Gastric neoplasia; Incidence; Intestinal-type gastric cancer; Prevalence; Risk factors; Type I gastric carcinoid

Mesh:

Year:  2012        PMID: 22493541      PMCID: PMC3319954          DOI: 10.3748/wjg.v18.i12.1279

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  72 in total

1.  Gastritis staging in clinical practice: the OLGA staging system.

Authors:  Massimo Rugge; Alberto Meggio; Gianmaria Pennelli; Francesco Piscioli; Luciano Giacomelli; Giovanni De Pretis; David Y Graham
Journal:  Gut       Date:  2006-12-01       Impact factor: 23.059

Review 2.  Review article: Pathogenesis and management of gastric carcinoid tumours.

Authors:  M D Burkitt; D M Pritchard
Journal:  Aliment Pharmacol Ther       Date:  2006-11-01       Impact factor: 8.171

3.  Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.

Authors:  Kurt Borch; Bo Ahrén; Håkan Ahlman; Sture Falkmer; Göran Granérus; Lars Grimelius
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

4.  Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection.

Authors:  E Lahner; C Bordi; M S Cattaruzza; C Iannoni; M Milione; G Delle Fave; B Annibale
Journal:  Aliment Pharmacol Ther       Date:  2005-09-01       Impact factor: 8.171

5.  Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany.

Authors:  M N Weck; C Stegmaier; D Rothenbacher; H Brenner
Journal:  Aliment Pharmacol Ther       Date:  2007-09-15       Impact factor: 8.171

Review 6.  The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis.

Authors:  Theodoros Rokkas; Dimitios Pistiolas; Panos Sechopoulos; Ioannis Robotis; Georgios Margantinis
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

Review 7.  Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading.

Authors:  M Rugge; P Correa; M F Dixon; R Fiocca; T Hattori; J Lechago; G Leandro; A B Price; P Sipponen; E Solcia; H Watanabe; R M Genta
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

8.  Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.

Authors:  L Lundell; N Havu; P Miettinen; H E Myrvold; L Wallin; R Julkunen; K Levander; J G Hatlebakk; B Liedman; M Lamm; A Malm; A Walan
Journal:  Aliment Pharmacol Ther       Date:  2006-03-01       Impact factor: 8.171

9.  Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.

Authors:  Annemarie C de Vries; Nicole C T van Grieken; Caspar W N Looman; Mariël K Casparie; Esther de Vries; Gerrit A Meijer; Ernst J Kuipers
Journal:  Gastroenterology       Date:  2008-01-30       Impact factor: 22.682

10.  Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia.

Authors:  W Ye; O Nyrén
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  36 in total

1.  Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis.

Authors:  Sangho Jeong; Eunyoung Choi; Christine P Petersen; Joseph T Roland; Alessandro Federico; Rossana Ippolito; Francesco P D'Armiento; Gerardo Nardone; Osamu Nagano; Hideyuki Saya; Marco Romano; James R Goldenring
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 2.  Pathophysiology of Gastric NETs: Role of Gastrin and Menin.

Authors:  Sinju Sundaresan; Anthony J Kang; Juanita L Merchant
Journal:  Curr Gastroenterol Rep       Date:  2017-07

3.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

4.  Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers.

Authors:  Yi-Fang Han; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

5.  Intestinal metaplasia surveillance: searching for the road-map.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Repici; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

Review 6.  Autoimmune gastritis: Pathologist's viewpoint.

Authors:  Irene Coati; Matteo Fassan; Fabio Farinati; David Y Graham; Robert M Genta; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 7.  Autoimmune atrophic gastritis--pathogenesis, pathology and management.

Authors:  William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-18       Impact factor: 46.802

8.  Gastric cancer in patients with type I gastric carcinoids.

Authors:  Edith Lahner; Gianluca Esposito; Emanuela Pilozzi; Gloria Galli; Vito D Corleto; Emilio Di Giulio; Bruno Annibale
Journal:  Gastric Cancer       Date:  2014-06-03       Impact factor: 7.370

9.  Recurrent gastric neuroendocrine tumors treated with total gastrectomy.

Authors:  Myounghwa Jung; Jung-Wook Kim; Jae-Young Jang; Young Woon Chang; Sun Hee Park; Yong Ho Kim; Youn Wha Kim
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

10.  Profiles of gene polymorphisms in cytokines and Toll-like receptors with higher risk for gastric cancer.

Authors:  Juliana Garcia de Oliveira; Ana Flávia Teixeira Rossi; Daniela Manchini Nizato; Kenji Miyasaki; Ana Elizabete Silva
Journal:  Dig Dis Sci       Date:  2012-10-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.